This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
His T7 expression technology can be used to make large quantities of nearly any RNA or protein and has been for decades, and continues to be, a mainstay of biomedical research and pharmaceutical production. There’s not a single molecularbiology or biochemistry lab I know that doesn’t use T7.” and around the world.
With more than 20 years of experience in business management, strategy, marketing and product management, Anis also has a research background in biotech, pharmaceutical and premier academic organisations. Anis also serves on the scientific and editorial advisory board of Genetic Engineering News at Mary Ann Liebert, Inc. Biotechnol Prog.
The Phase II clinical trial will evaluate Ultimovacs’ proprietary universal cancer vaccine, UV1, in combination with AstraZeneca’s durvalumab and olaparib in patients with relapsed ovarian cancer. UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. Mogrify – U.K.-based
Link Gene Expression & Regulation →Genetic regulatory mechanisms in the synthesis of proteins , by Jacob F. & Journal of MolecularBiology (1961). Link (Golden Gate assembly) Other Basic Methods & Cloning →Basic Methods in Cellular and MolecularBiology , by multiple authors. Nature (2011).
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content